Every Form 4 that Monte Rosa Therapeutics, Inc. (GLUE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GLUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLUE filings page.
Monte Rosa Therapeutics, Inc. (GLUE) Principal Accounting Officer Matthew Bowen sold 13 shares of common stock on October 5, 2026, at $10.56 per share. The shares were required to be sold to cover tax withholding obligations tied to restricted stock unit vesting; the sales were automatic and not at his discretion. He directly held 25,891 shares after the transaction.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported an open-market sale of 9,500 shares of Common Stock on July 16, 2026. The shares were sold at a weighted average price of $23.1809 per share, with individual trades between $23.18 and $23.23. Following this transaction, Warmuth directly holds 585,038 shares of Monte Rosa Therapeutics. The transaction is not indicated as made under a Rule 10b5-1 trading plan.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported option-related trades in common stock. She exercised stock options to acquire 4,351 shares at $3.98 per share and, on the same date, sold 4,351 shares at a weighted average price of $23.3808 under a Rule 10b5-1 trading plan adopted on February 19, 2026.
After these transactions, she directly holds 62,371 common shares and 26,947 stock options (right to buy) expiring on June 3, 2034. The sale transactions occurred in a price range of $22.83 to $23.71 per share.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an exercise-and-sell transaction in company stock. On July 6, 2026, she exercised options to acquire 6,000 shares of common stock at $6.14 per share and sold a total of 6,000 shares in open-market trades, including 400 shares at $24.13 and additional shares at a weighted average price of $23.2495 within a range of $22.97 to $23.65. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the trades, she directly holds 67,845 shares of common stock.
Monte Rosa Therapeutics director-linked funds restructured their holdings without market trades. On July 1, 2026, New Enterprise Associates 17, L.P. made a pro rata distribution of 1,000,000 shares of Monte Rosa Therapeutics common stock to its general and limited partners for no consideration. NEA Partners 17 both received and later distributed 15,000 shares, also for no consideration. Director Ali Behbahani is a manager of the related general partners and disclaims beneficial ownership of shares in which he has no pecuniary interest, so these entries reflect internal reallocations among NEA-affiliated entities rather than open-market buying or selling.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku exercised stock options and sold shares in a pre-planned transaction. On June 30, he exercised options to acquire 5,407 shares of common stock at $13.41 per share, then sold 5,407 shares at $24.50 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. After these transactions, he directly owned 60,612 shares of common stock, including 620 shares acquired through the company’s 2021 Employee Stock Purchase Program on June 30, 2026.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 6,000 shares of Common Stock at $7.56 per share and on the same date sold 6,000 shares at $22.95 per share in an open-market transaction.
After these transactions, Janku directly holds 59,992 shares of Common Stock and retains 60,000 stock options that remain outstanding and fully vested. The company notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating they were scheduled in advance rather than timed discretionarily.
Monte Rosa Therapeutics director Anthony M. Manning reported an exercise-and-sale transaction in the company’s common stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then completed an open-market sale of 10,000 shares at $23.11 per share on the same date.
Following these transactions, his reported direct common stock holdings were 0 shares, while a stock option position for 2,100 shares remained outstanding, with an expiration date in 2034. The filing characterizes the stock transaction as an open-market sale.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported option exercises and share sales in GLUE stock. On June 23–24, he exercised options to acquire 36,000 shares of common stock at $7.56 per share and sold a total of 41,845 shares in open-market transactions at weighted average prices of $20.2214 and $21.4227 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026. After the transactions, he directly holds 59,992 shares of Monte Rosa common stock.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 2,175 shares of common stock at $3.98 per share, then sold 2,175 shares in an open-market transaction at $20.00 per share.
After these transactions, she directly holds 62,371 shares of common stock and 31,298 stock options. The filing notes that the trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an option exercise and share sale in company stock. On June 23, 2026, she exercised options to acquire 3,000 shares of common stock at $6.14 per share and sold 3,000 shares at $20.00 per share in an open-market transaction.
After these transactions, she directly owned 67,845 shares of common stock and held 203,290 stock options exercisable at $6.14 per share, expiring on April 12, 2031. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale under a pre-arranged plan. She exercised stock options for 2,176 shares of common stock at $3.98 per share and sold 2,176 shares in an open-market transaction at $19.00 per share, all on June 17, 2026 pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2026. Following these transactions, she directly owns 62,371 common shares and holds 33,473 stock options.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson exercised options for 3,000 shares of common stock at $6.14 per share and on the same day sold 3,000 shares at $19.00 per share in an open-market transaction. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Townson directly holds 67,845 common shares, along with 206,290 stock options that remain outstanding.
Monte Rosa Therapeutics director Ali Behbahani received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Monte Rosa Therapeutics director Andrew N. Schiff received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and were awarded as compensation, not through open-market buying or selling.
The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options covering 25,800 underlying shares directly.
Monte Rosa Therapeutics director Anthony M. Manning received a grant of stock options for 25,800 shares of Common Stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, provided he continues in service until that time. Following this grant, he holds 25,800 derivative securities representing rights to acquire common shares.
Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. Following this grant, he holds options for 25,800 shares. The options vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as he continues serving the company.
Monte Rosa Therapeutics director Kimberly Blackwell received a grant of stock options on Common Stock. The award covers 25,800 options, each with an exercise price of $17.10 per share, giving her the right to buy an equal number of shares in the future.
These options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as she continues serving until that time. After this grant, she holds 25,800 derivative securities from this award, which expire on June 11, 2036 if not exercised.
Monte Rosa Therapeutics director Eric A. Hughes received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. This is a compensation-related equity award, not an open-market purchase.
All 25,800 options will vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Hughes holds 25,800 stock options directly.
Monte Rosa Therapeutics director Christine Siu received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to her continued service.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported open-market sales of a total of 5,466 shares of common stock on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, at weighted average prices around the high-$18 to high-$19 range.
Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported a small, routine option exercise and share sale. She exercised stock options to acquire 6,000 shares of common stock at $6.14 per share, then sold 6,000 shares in an open-market transaction at a weighted average price of $19.87 per share.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After the sale, Townson directly holds 67,845 shares of common stock and 209,290 stock options following the derivative transaction.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale in Common Stock. She exercised stock options for 2,175 shares at $3.98 per share and sold 2,175 shares in an open-market transaction at $20.00 per share.
After these transactions, she directly holds 62,371 shares of Common Stock and 35,649 stock options. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating a scheduled liquidity event rather than a discretionary trade.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options to acquire 2,176 shares of common stock at $3.98 per share and, on the same date, completed an open-market sale of 2,176 shares at $19.00 per share. After these transactions, she directly held 62,371 shares of Monte Rosa Therapeutics common stock. The filing notes that the transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating they were scheduled in advance.
Monte Rosa Therapeutics director Anthony M. Manning reported an option exercise-and-sale transaction in the company’s stock. He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $4.16 per share, then sold 10,000 shares in an open-market transaction at $18.01 per share on the same date.
Following these transactions, Manning reported holding no shares of common stock directly, while retaining stock options covering 12,100 shares at a $4.16 exercise price that are fully vested and exercisable and expire on June 12, 2034.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,467 shares of common stock. The shares were sold at a weighted average price of $18.922 per share, in multiple trades between $18.67 and $19.38.
After the transaction, Warmuth directly holds 600,004 shares of Monte Rosa Therapeutics. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, indicating the transaction timing was set in advance rather than being purely discretionary.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 8,000 shares of Common Stock. The sale occurred on April 14, 2026 at a weighted average price of $17.6406 per share, with individual trade prices ranging from $17.64 to $17.65. After this transaction, he directly holds 605,471 shares of Monte Rosa Therapeutics common stock, indicating he retains a substantial equity position in the company.
Monte Rosa Therapeutics’ Chief Business & Legal Officer, Nickson Philip, sold 5,845 shares of common stock in an open-market transaction. The sale on April 9, 2026 was executed at a weighted average price of $17.6925 per share, based on multiple trades within a narrow range. After this sale, he directly holds 55,000 shares of Monte Rosa Therapeutics common stock.
Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards. He was granted a stock option covering 19,500 shares of common stock at an exercise price of $16.93 per share, expiring on April 5, 2036. Separately, he received 4,300 restricted stock units, each representing one share upon vesting. The RSUs vest 25% on April 6, 2027, with the remainder in three equal annual installments, while the option vests 25% on April 6, 2027 and then in 36 substantially equal monthly installments, in each case subject to continued service. Following the RSU grant, he directly owns 25,904 shares of common stock.
Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn reported an automatic sale of 139 shares of common stock. The shares were sold on March 4, 2026 at a price of $17.96 per share to cover tax withholding obligations triggered by the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at Dunn’s discretion. After this tax-related transaction, he beneficially owned 22,554 shares of Monte Rosa Therapeutics common stock directly.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,466 shares of common stock at a weighted average price of $17.9243 per share on March 2, 2026. The trades occurred between $17.50 and $18.46 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, he directly holds 613,471 shares of Monte Rosa Therapeutics common stock.
Monte Rosa Therapeutics principal accounting officer Edmund Dunn reported option exercises paired with share sales. On February 27 and March 2, 2026, he exercised stock options to acquire common shares at an exercise price of $13.41 per share.
He then sold a total of 25,700 common shares in open-market transactions, including a weighted-average sale price of $18.1015 per share for one block and $17.50 per share for another. After these trades, Dunn directly owned 22,693 Monte Rosa Therapeutics shares.
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock. On February 23, 2026, he sold 9,189 shares of common stock at an average price of $19.4973 per share and now directly owns 65,837 shares.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported open-market sales of company common stock on January 7, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. He sold 3,707 shares at a weighted average price of $23.2422, 1,450 shares at $23.8762, and 309 shares at $24.5736, for a total of 5,466 shares sold.
The filing notes that each weighted average price reflects multiple trades, with sale prices ranging from $22.42 to $24.65. After these transactions, Warmuth beneficially owned 618,937 shares of Monte Rosa common stock in direct ownership.